["CYP3A4 Inhibitors: Ketoconazole, an inhibitor of the drug metabolizing enzyme CYP3A4, significantly increased plasma concentrations of tolterodine when coadministered to subjects who were poor metabolizers (see CLINICAL PHARMACOLOGY, Variability in Metabolism and Drug-Drug Interactions).\n\n###\n\n", " mechanism END"]
["For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily.\n\n###\n\n", " advise END"]
["Given the primary CNS effects of paliperidone, INVEGA    should be used with caution in combination with other centrally acting drugs and alcohol.\n\n###\n\n", " advise END"]
["Paliperidone may antagonize the effect of levodopa and other dopamine agonists.\n\n###\n\n", " effect END"]
["The concomitant use of oxybutynin with other anticholinergic drugs or with other agents which produce dry mouth, constipation, somnolence (drowsiness), and/or other anticholinergic-like effects may increase the frequency and/or severity of such effects.\n\n###\n\n", " effect END"]
["Mean oxybutynin chloride plasma concentrations were approximately 2 fold higher when DITROPAN XL was administered with ketoconazole, a potent CYP3A4 inhibitor.\n\n###\n\n", " mechanism END"]
["Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC).\n\n###\n\n", " mechanism END"]
["Mitotane has been reported to accelerate the metabolism of warfarin by the mechanism of hepatic microsomal enzyme induction, leading to an increase in dosage requirements for warfarin.\n\n###\n\n", " mechanism END"]
["Therefore, physicians should closely monitor patients for a change in anticoagulant dosage requirements when administering Mitotane to patients on coumarin-type anticoagulants.\n\n###\n\n", " advise END"]
["Concomitant administration of vancomycin and anesthetic agents has been associated with erythema and histamine-like flushing and anaphylactoid reactions.\n\n###\n\n", " effect END"]
["Coadministration of TRITEC with clarithromycin resulted in increased plasma ranitidine concentrations (57%), increased plasma bismuth trough concentrations (48%), and increased 14- hydroxy- clarithromycin plasma concentrations (31%).\n\n###\n\n", " mechanism END"]
["Coadministration with a high dose of antacid (170 mEq) results in a 28% decrease in plasma concentrations of ranitidine and may decrease plasma concentrations of bismuth from TRITEC.\n\n###\n\n", " mechanism END"]
["However, the co   administration of SPIRIVA with other anticholinergic   containing drugs (e.g., ipratropium) has not been studied and is therefore not recommended.\n\n###\n\n", " advise END"]
["Prothrombin time or other suitable anticoagulation test should be monitored if tigecycline is administered with warfarin.\n\n###\n\n", " advise END"]
["Concurrent use of antibacterial drugs with oral contraceptives may render oral contraceptives less effective.\n\n###\n\n", " effect END"]
["Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers.\n\n###\n\n", " effect END"]
["The effects of anticholinergic drugs, such as atropine and tricyclic antidepressants may be enhanced by the concomitant administration of triprolidine.\n\n###\n\n", " effect END"]
["Caution should be exercised when Methergine    (methylergonovine maleate) is used concurrently with other vasoconstrictors or ergot alkaloids.\n\n###\n\n", " advise END"]
["Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include erythromycin, rifampin, rifabutin, ketoconazole, and fluconazole.\n\n###\n\n", " effect END"]
["In vitro perfusion of isolated rat liver has shown that cimetidine caused a significant reduction in trimetrexate metabolism and that acetaminophen altered the relative concentration of trimetrexate metabolites possibly by competing for sulfate metabolites.\n\n###\n\n", " mechanism END"]
["Based on an in vitro rat liver model, nitrogen substituted imidazole drugs (clotrimazole, ketoconazole, miconazole) were potent, non-competitive inhibitors of trimetrexate metabolism.\n\n###\n\n", " mechanism END"]
["The use of AGGRASTAT, in combination with heparin and aspirin, has been associated with an increase in bleeding compared to heparin and aspirin alone (see\n\n###\n\n", " effect END"]
["however, in patients with Paget's Disease prior diphosphonate use appears to reduce the anti-resorptive response to Calcitonin (salmon) nasal spray.\n\n###\n\n", " effect END"]
["Because Matulane exhibits some monoamine oxidase inhibitory activity, sympathomimetic drugs, tricyclic antidepressant drugs (e.g., amitriptyline HCl, imipramine HCl) and other drugs and foods with known high tyramine content, such as wine, yogurt, ripe cheese and bananas, should be avoided.\n\n###\n\n", " advise END"]
["patients receiving lithium and Neulasta should have more frequent monitoring of neutrophil counts.\n\n###\n\n", " advise END"]
["Sirolimus AUC was increased by 21% with no effect on Cmax in the presence of steady-state MYCAMINE compared with sirolimus alone.\n\n###\n\n", " mechanism END"]
["Nifedipine AUC and Cmax were increased by 18% and 42%, respectively, in the presence of steady-state MYCAMINE compared with nifedipine alone.\n\n###\n\n", " mechanism END"]
["Patients receiving sirolimus or nifedipine in combination with MYCAMINE should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary.\n\n###\n\n", " advise END"]
["Dosages of concomitantly administered opioids should be reduced by approximately half, because levomepromazine amplifies the therapeutic actions and side-effects of opioids.\n\n###\n\n", " effect END"]
["Additive sedative effects and confusional states may emerge if levomepromazine is given with benzodiazepines or barbiturates.\n\n###\n\n", " effect END"]
["Exert particular caution in combining levomepromazine with other anticholinergic drugs (tricyclic antidepressants and antiparkinsonian-agents): Particularly the elderly may develop delirium, high fever, severe obstipation, even ileus and glaucoma.\n\n###\n\n", " advise END"]
["Caffeine and/or stimulantes of the ephedrine/amphetamine type may counteract the specific actions of levomepromazine.\n\n###\n\n", " effect END"]
["Prior administration of succinylcholine can potentiate the neuromuscular blocking effects of nondepolarizing agents.\n\n###\n\n", " effect END"]
["Evidence of spontaneous recovery from succinylcholine should be observed before the administration of MIVACRON.\n\n###\n\n", " advise END"]
["Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.\n\n###\n\n", " int END"]
["The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine.\n\n###\n\n", " effect END"]
["While the effects of chronic phenytoin or carbamazepine therapy on the action of MIVACRON are unknown, slightly shorter durations of neuromuscular block may be anticipated and infusion rate requirements may be higher.\n\n###\n\n", " effect END"]
["Do not exceed a 5 mg daily dose of VESIcare when administered with therapeutic doses of ketoconazole or other potent CYP3A4 inhibitors.\n\n###\n\n", " advise END"]
["Interaction with Guanethidine: Although minoxidil does not itself cause orthostatic hypotension, its administration to patients already receiving guanethidine can result in profound orthostatic effects.\n\n###\n\n", " effect END"]
["If at all possible guanethidine should be discontinued well before minoxidil is begun.\n\n###\n\n", " advise END"]
["While co-administration of ZAVESCA    appeared to increase the clearance of Cerezyme by 70%, these results are not conclusive because of the small number of subjects studied and because patients took variable doses of Cerezyme.\n\n###\n\n", " mechanism END"]
["Combination therapy with Cerezyme    (imiglucerase) and ZAVESCA    is not indicated.\n\n###\n\n", " advise END"]
["Aminoglutethimide administered concomitantly with depo-subQ provera 104 may significantly decrease the serum concentrations of MPA.\n\n###\n\n", " mechanism END"]
["Thiazides may decrease arterial responsiveness to norepinephrine.\n\n###\n\n", " effect END"]
["Thiazide drugs may increase the responsiveness of tubocurarine.\n\n###\n\n", " effect END"]
["Lithium renal clearance is reduced by thiazides, increasing the risk of lithium toxicity.\n\n###\n\n", " mechanism END"]
["Thiazides may add to or potentiate the action of other antihypertensive drugs.\n\n###\n\n", " effect END"]
["Diuretics: Patients on diuretics, and especially those started recently, may occasionally experience an excessive reduction of blood pressure after initiation of ACEON    Tablets therapy.\n\n###\n\n", " effect END"]
["The possibility of hypotensive effects can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with perindopril.\n\n###\n\n", " effect END"]
["If diuretics cannot be interrupted, close medical supervision should be provided with the first dose of ACEON    Tablets, for at least two hours and until blood pressure has stabilized for another hour.\n\n###\n\n", " advise END"]
["Digoxin: A controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with ACEON    Tablets, but an effect of digoxin on the plasma concentration of perindopril/perindoprilat has not been excluded.\n\n###\n\n", " mechanism END"]
["Gentamicin: Animal data have suggested the possibility of interaction between perindopril and gentamicin.\n\n###\n\n", " int END"]
["Concurrent use of alcohol and other CNS depression-producing drugs may increase the CNS depressant effects of methyprylon or these other medications.\n\n###\n\n", " effect END"]
["Administration of valproic acid decreases oral clearance of temozolomide by about 5%.\n\n###\n\n", " mechanism END"]
["In a study in which 34 different drugs were tested, therapeutically relevant concentrations of tolbutamide, sodium salicylate and sulfamethizole displaced protein-bound teniposide in fresh human serum to a small but significant extent.\n\n###\n\n", " mechanism END"]
["An increase in intracellular levels of methotrexate was observed in vitro in the presence of teniposide.\n\n###\n\n", " mechanism END"]
["Anticoagulants (oral): The activity of oral anticoagulants may be potentiated by anti-vitamin-K activity attributed to methimazole.\n\n###\n\n", " effect END"]
["Decreased seizure threshold has been reported in patients receiving CYLERT concomitantly with antiepileptic medications.\n\n###\n\n", " effect END"]
["Diuretics: Furosemide and probably other loop diuretics given concomitantly with metolazone can cause unusually large or prolonged losses of fluid and electrolytes.\n\n###\n\n", " effect END"]
["Other Antihypertensives: When MYKROX Tablets are used with other antihypertensive drugs, care must be taken, especially during initial therapy.\n\n###\n\n", " advise END"]
["Digitalis Glycosides: Diuretic-induced hypokalemia can increase the sensitivity of the myocardium to digitalis.\n\n###\n\n", " effect END"]
["Curariform Drugs: Diuretic-induced hypokalemia may enhance neuromuscular blocking effects of curariform drugs (such as tubocurarine) the most serious effect would be respiratory depression which could proceed to apnea.\n\n###\n\n", " effect END"]
["Salicylates and Other Non-Steroidal Anti-Inflammatory Drugs: May decrease the antihypertensive effects of MYKROX Tablets.\n\n###\n\n", " effect END"]
["Sympathomimetics: Metolazone may decrease arterial responsiveness to norepinephrine, but this diminution is not sufficient to preclude effectiveness of the pressor agent for therapeutic use.\n\n###\n\n", " effect END"]
["Methenamine: Efficacy may be decreased due to urinary alkalizing effect of metolazone.\n\n###\n\n", " effect END"]
["Anticoagulants: Metolazone, as well as other thiazide-like diuretics, may affect the hypoprothrombinemic response to anticoagulants;\n\n###\n\n", " effect END"]
["The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.\n\n###\n\n", " effect END"]
["Anticholinergics antagonize the effects of antiglaucoma agents.\n\n###\n\n", " effect END"]
["Anticholinergic drugs in the presence of increased intraocular pressure may be hazardous when taken concurrently with agents such as corticosteroids.\n\n###\n\n", " effect END"]
["Anticholinergic agents may affect gastrointestinal absorption of various drugs, such as slowly dissolving dosage forms of digoxin;\n\n###\n\n", " mechanism END"]
["Anticholinergic drugs may antagonize the effects of drugs that alter gastrointestinal motility, such as metoclopramide.\n\n###\n\n", " effect END"]
["Because antacids may interfere with the absorption of anticholinergic agents, simultaneous use of these drugs should be avoided.\n\n###\n\n", " mechanism END"]
["Ropivacaine should be used with caution in patients receiving other local anesthetics or agents structurally related to amide-type local anesthetics, since the toxic effects of these drugs are additive.\n\n###\n\n", " advise END"]
["In vivo, the plasma clearance of ropivacaine was reduced by 70% during coadministration of fluvoxamine (25 mg bid for 2 days), a selective and potent CYP1A2 inhibitor.\n\n###\n\n", " mechanism END"]
["Thus strong inhibitors of cytochrome P4501A2, such as fluvoxamine, given concomitantly during administration of Ropivacaine, can interact with Ropivacaine leading to increased ropivacaine plasma levels.\n\n###\n\n", " int END"]
["Coadministration of a selective and potent inhibitor of CYP3A4, ketoconazole (100 mg bid for 2 days with ropivacaine infusion administered 1 hour after ketoconazole) caused a 15% reduction in in-vivo plasma clearance of ropivacaine.\n\n###\n\n", " mechanism END"]
["It has been reported that sulfamethoxazole may prolong the prothrombin time in patients who are receiving the anticoagulant warfarin.\n\n###\n\n", " effect END"]
["Sulfamethoxazole may inhibit the hepatic metabolism of phenytoin.\n\n###\n\n", " mechanism END"]
["At a 1.6-g dose, sulfamethoxazole produced a slight but significant increase in the half-life of phenytoin but did not produce a corresponding decrease in the metabolic clearance rate.\n\n###\n\n", " mechanism END"]
["Sulfonamides can also displace methotrexate from plasma protein-binding sites, thus increasing free methotrexate concentrations.\n\n###\n\n", " mechanism END"]
["There is usually complete cross-resistance between PURINETHOL (mercaptopurine) and TABLOID brand Thioguanine.\n\n###\n\n", " effect END"]
["As there is in vitro evidence that aminosalicylate derivatives (e.g., olsalazine, mesalazine, or sulphasalazine) inhibit the TPMT enzyme, they should be administered with caution to patients receiving concurrent thioguanine therapy.\n\n###\n\n", " mechanism END"]
["Thalidomide has been reported to enhance the sedative activity of barbiturates, alcohol, chlorpromazine, and reserpine.\n\n###\n\n", " effect END"]
["John's Wort with hormonal contraceptive agents may reduce the effectiveness of the contraception and up to one month after discontinuation of these concomitant therapies.\n\n###\n\n", " effect END"]
["Catecholamine-depleting drugs (e.g., reserpine) may have an additive effect when given with beta-blocking agents.\n\n###\n\n", " effect END"]
["The CNS-depressant effect of propoxyphene is additive with that of other CNS depressants, including alcohol.\n\n###\n\n", " effect END"]
["It is reasonable to employ appropriate clinical monitoring when potent cytochrome P450 enzyme inducers, such as phenobarbital or rifampin, are co-administered with montelukast.\n\n###\n\n", " advise END"]
["It is reasonable to employ appropriate clinical monitoring when potent cytochrome P450 enzyme inducers, such as phenobarbital or rifampin, are co-administered with montelukast.\n\n###\n\n", " advise END"]
["Cimetidine: Cimetidine, a known inhibitor of renal tubular secretion of organic bases via the cationic transport system, caused a 50% increase in pramipexole AUC and a 40% increase in half-life (N= 12).\n\n###\n\n", " mechanism END"]
["Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.\n\n###\n\n", " mechanism END"]
["Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX.\n\n###\n\n", " effect END"]
["There have been postmarketing reports of increased INR and prothrombin time in patients receiving proton pump inhibitors, including pantoprazole, and warfarin concomitantly.\n\n###\n\n", " effect END"]
["Patients treated with proton pump inhibitors and warfarin concomitantly should be monitored for increases in INR and prothrombin time.\n\n###\n\n", " advise END"]
["Because of profound and long lasting inhibition of gastric acid secretion, pantoprazole may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (eg, ketoconazole, ampicillin esters, and iron salts).\n\n###\n\n", " mechanism END"]
["Other eye drops or medications such as acetylcholine chloride (Miochol) and carbachol (Carboptic, Isopto Carbachol) may decrease the effects of suprofen ophthalmic.\n\n###\n\n", " effect END"]
["You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days.\n\n###\n\n", " advise END"]
["Changes in insulin and other diabetes drug therapies may be necessary during treatment with mazindol.\n\n###\n\n", " advise END"]
["Mazindol may reduce the effects of guanethidine (Ismelin).\n\n###\n\n", " effect END"]
["Ethanol decreases the elimination of abacavir causing an increase in overall exposure . The addition of methadone has no clinically significant effect on the pharmacokinetic properties of abacavir.\n\n###\n\n", " mechanism END"]
["In a study of 11 HIV-infected patients receiving methadone-maintenance therapy (40 mg and 90 mg daily) with 600 mg of ZIAGEN twice daily (twice the currently recommended dose), oral methadone clearance increased 22% (90% CI 6% to 42%).\n\n###\n\n", " mechanism END"]
["Sulfoxone may increase the effects of barbiturates, tolbutamide, and uricosurics.\n\n###\n\n", " effect END"]
["Phenothiazines are capable of potentiating CNS depressants (e.g., barbiturates, anesthetics, opiates, alcohol, etc.)\n\n###\n\n", " effect END"]
["A pharmacokinetic study demonstrated that coadministration of megestrol acetate and indinavir results in a significant decrease in the pharmacokinetic parameters (~36% for Cmax and ~28% for AUC) of indinavir.\n\n###\n\n", " mechanism END"]
["Administration of a higher dose of indinavir should be considered when coadministering with megestrol acetate.\n\n###\n\n", " advise END"]
["Streptozocin has been reported to prolong the elimination half-life of doxorubicin and may lead to severe bone marrow suppression;\n\n###\n\n", " mechanism END"]
["a reduction of the doxorubicin dosage should be considered in patients receiving ZANOSAR concurrently.\n\n###\n\n", " advise END"]
["The concurrent use of streptozocin and phenytoin has been reported in one case to result in reduced streptozocin cytotoxicity.\n\n###\n\n", " effect END"]
["ARAMINE should be used with caution in digitalized patients, since the combination of digitalis and sympathomimetic amines may cause ectopic arrhythmias.\n\n###\n\n", " effect END"]
["Monoamine oxidase inhibitors or tricyclic antidepressants may potentiate the action of sympathomimetic amines.\n\n###\n\n", " effect END"]
["Mequitazine can interact with CNS depressant, antichlolinergic, TCA, MAOIs, and alcohol.\n\n###\n\n", " int END"]
["Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, corticosteroids, anticoagulants, and beta blockers.\n\n###\n\n", " int END"]
["Sulfamethizole may increase the effects of barbiturates, tolbutamide, and uricosurics.\n\n###\n\n", " effect END"]
["Anticoagulants (such as heparin and vitamin K antagonists) and drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after TNKase therapy.\n\n###\n\n", " effect END"]
["When a single 100 mg dose of rimantadine HCl was administered one hour after the initiation of Cimetidine (300 mg four times a day), the apparent total rimantadine clearance of this single dose in normal healthy adults was reduced by 18% (compared to the apparent total rimantadine clearance in the same subjects in the absence of cimetidine).\n\n###\n\n", " mechanism END"]
["Coadministration with acetaminophen reduced the peak concentration and AUC values for rimantadine by approximately 11%.\n\n###\n\n", " mechanism END"]
["Peak plasma concentrations and AUC of rimantadine were reduced approximately 10% in the presence of aspirin.\n\n###\n\n", " mechanism END"]
["Trimethoprim may inhibit the hepatic metabolism of phenytoin.\n\n###\n\n", " mechanism END"]
["Trimethoprim, given at a common clinical dosage, increased the phenytoin half-life by 51% and decreased the phenytoin metabolic clearance rate by 30%.\n\n###\n\n", " mechanism END"]
["Pilocarpine should be administered with caution to patients taking beta adrenergic antagonists because of the possibility of conduction disturbances.\n\n###\n\n", " advise END"]
["Mutual inhibition of metabolism occurs with concurrent use of cyclosporin and methylprednisolone;\n\n###\n\n", " mechanism END"]
["convulsions have been reported with concurrent use of methylprednisolone and cyclosporin.\n\n###\n\n", " effect END"]
["Drugs that induce hepatic enzymes such as phenobarbital, phenytoin, and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response.\n\n###\n\n", " mechanism\nadvise END"]
["Drugs such as troleandomycin and ketoconazole may inhibit the metabolism of methylprednisolone and thus decrease its clearance.\n\n###\n\n", " mechanism END"]
["Methylprednisolone may increase the clearance of chronic high dose aspirin.\n\n###\n\n", " mechanism END"]
["This could lead to decreased salicylate serum levels or increase the risk of salicylate toxicity when methylprednisolone is withdrawn.\n\n###\n\n", " effect END"]
["Aspirin should be used cautiously in conjunction with corticosteroids in patients suffering from hypoprothrombinemia.\n\n###\n\n", " advise END"]
["There are reports of enhanced as well as diminished effects of anticoagulant when given concurrently with corticosteroids.\n\n###\n\n", " effect END"]
["The effects of metoclopramide on gastrointestinal motility are antagonized by anticholinergic drugs and narcotic analgesics.\n\n###\n\n", " effect END"]
["Additive sedative effects can occur when metoclopramide is given with alcohol, sedatives, hypnotics, narcotics, or tranquilizers.\n\n###\n\n", " effect END"]
["The finding that metoclopramide releases catecholamines in patients with essential hypertension suggests that it should be used cautiously, if at all, in patients receiving monoamine oxi-dase inhibitors.\n\n###\n\n", " advise END"]
["Absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa, ethanol, cyclosporine).\n\n###\n\n", " mechanism END"]
["Because the action of metoclopramide will influence the delivery of food to the intestines and thus the rate of absorption, insulin dosage or timing of dosage may require adjustment.\n\n###\n\n", " advise END"]
["Vasopressors, particularly metaraminol, may cause serious cardiac arrhythmias during halothane anesthesia and therefore should be used only with great caution or not at all.\n\n###\n\n", " effect END"]
["MAO Inhibitors: The pressor effect of sympathomimetic pressor amines is markedly potentiated in patients receiving monoamine oxidase inhibitors (MAOI).\n\n###\n\n", " effect END"]
["The pressor response of adrenergic agents may also be potentiated by tricyclic antidepressants.\n\n###\n\n", " effect END"]
["Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).\n\n###\n\n", " int END"]
["Due to its effects on gastric emptying, SYMLIN therapy should not be considered for patients taking drugs that alter gastrointestinal motility (e.g., anticholinergic agents such as atropine) and agents that slow the intestinal absorption of nutrients (e.g., alpha glucosidase inhibitors).\n\n###\n\n", " advise END"]
["When the rapid onset of a concomitant orally administered agent is a critical determinant of effectiveness (such as analgesics), the agent should be administered at least 1 hour prior to or 2 hours after SYMLIN injection.\n\n###\n\n", " advise END"]
["Mixing SYMLIN and Insulin The pharmacokinetic parameters of SYMLIN were altered when mixed with regular, NPH, and 70/30 premixed formulations of recombinant human insulin immediately prior to injection.\n\n###\n\n", " mechanism END"]
["Patients receiving antibiotics and sulfonamides generally should not be treated with ganglion blockers.\n\n###\n\n", " advise END"]
["The action of Mecamylamine may be potentiated by anesthesia, other antihypertensive drugs and alcohol.\n\n###\n\n", " effect END"]
["Oral metronidazole has been reported to potentiate the anticoagulant effect of coumarin and warfarin, resulting in a prolongation of prothrombin time.\n\n###\n\n", " effect END"]
["Concomitant use of alcohol with phentermine hydrochloride may result in an adverse drug interaction.\n\n###\n\n", " int END"]
["Other short-acting beta adrenergic aerosol bronchodilators should not be used concomitantly with MAXAIR AUTOHALER because they may have additive effects.\n\n###\n\n", " advise END"]
["A study published in 2002 found that vigabatrin causes a statistically significant increase in plasma clearance of carbamazepine.\n\n###\n\n", " mechanism END"]
["In 1984, Drs Rimmer and Richens at the University of Wales reported that administering vigabatrin with phenytoin lowered the serum phenytoin concentration in patients with treatment-resistant epilepsy.\n\n###\n\n", " mechanism END"]
["Anticholinesterases: Concurrent use of procaine hydrochloride and anticholinesterase agents may result in increased systemic toxicity since anticholinesterases inhibit the breakdown of procaine hydrochloride.\n\n###\n\n", " effect\nmechanism END"]
["CNS depressant medications: Concurrent use of procaine hydrochloride and CNS depressant medications may result in additive depressant effects.\n\n###\n\n", " effect END"]
["Hyaluronidase: Hyaluronidase may increase the diffusion rate of procaine hydrochloride, resulting in a decreased time of onset, but an increase in systemic toxicity.\n\n###\n\n", " mechanism END"]
["Neuromuscular blocking agents (such as suxamethonium chloride): Concurrent use of procaine hydrochloride and neuromuscular blocking agents may result in prolongation or enhancement of the neuromuscular blockade.\n\n###\n\n", " effect END"]
["Sulfonamides: Concurrent use of procaine hydrochloride and sulfonamides may result in a reduction of the antibacterial action of the sulfonamide.\n\n###\n\n", " effect END"]
["Acetazolamide: Concurrent use of acetazolamide and procaine hydrochloride may extend the plasma half-life of procaine.\n\n###\n\n", " mechanism END"]
["Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.\n\n###\n\n", " mechanism END"]
["Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations.\n\n###\n\n", " mechanism END"]
["Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response.\n\n###\n\n", " mechanism END"]
["Drugs such as troleandomycin and ketoconazole may inhibit the metabolism of corticosteroids and thus decrease their clearance.\n\n###\n\n", " mechanism END"]
["Corticosteroids may increase the clearance of chronic high dose aspirin.\n\n###\n\n", " mechanism END"]
["This could lead to decreased salicylate serum levels or increase the risk of salicylate toxicity when corticosteroid is withdrawn.\n\n###\n\n", " effect END"]
["Aspirin should be used cautiously in conjunction with corticosteroids in patients suffering from hypoprothrombinemia.\n\n###\n\n", " advise END"]
["The effect of corticosteroids on oral anticoagulants is variable.\n\n###\n\n", " effect END"]
["There are reports of enhanced as well as diminished effects of anticoagulants when given concurrently with corticosteroids.\n\n###\n\n", " effect END"]
["Interactions for Vitamin B1 (Thiamine):  Loop Diuretics, Oral Contraceptives, Stavudine, Tricyclic Antidepressants\n\n###\n\n", " int END"]
["Use with Anticholinergics: Because of their mechanism of action, cholinesterase inhibitors have the potential to interfere with the activity of anticholinergic medications.\n\n###\n\n", " int END"]
["Use with Cholinomimetics and Other Cholinesterase Inhibitors: A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar neuromuscular blocking agents or cholinergic agonists such as bethanechol.\n\n###\n\n", " effect END"]
["Ketoconazole: Spontaneous adverse reaction reports of patients taking concomitant ketoconazole with recommended doses of terfenadine demonstrate QT interval prolongation and rare serious cardiac events, e.g.\n\n###\n\n", " effect END"]
["Pharmacokinetic data indicate that ketoconazole markedly inhibits the metabolism of terfenadine, resulting in elevated plasma terfenadine levels.\n\n###\n\n", " mechanism END"]
["Concomitant administration of ketoconazole and terfenadine is contraindicated.\n\n###\n\n", " advise END"]
["Itraconazole: Torsades de pointes and elevated parent terfenadine levels have been reported during concomitant use of terfenadine and itraconazole in clinical trials of itraconazole and from foreign post-marketing sources.\n\n###\n\n", " mechanism END"]
["Concomitant administration of itraconazole and terfenadine is contraindicated.\n\n###\n\n", " advise END"]
["Due to the chemical similarity of other azole-type antifungal agents (including fluconazole, metronidazole, and miconazole) to ketoconazole, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions.\n\n###\n\n", " advise END"]
["Macrolides: Clinical drug interaction studies indicate that erythromycin and clarithromycin can exert an effect on terfenadine metabolism by a mechanism which may be similar to that of ketoconazole, but to a lesser extent.\n\n###\n\n", " mechanism END"]
["Concomitant administration of terfenadine with clarithromycin, erythromycin, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including azithromycin, is not recommended.\n\n###\n\n", " advise END"]
["Caution is recommended when administering NEXAVAR with compounds that are metabolized/eliminated predominantly by the UGT1A1 pathway (e.g. irinotecan).\n\n###\n\n", " advise END"]
["Concomitant treatment with NEXAVAR resulted in a 21% increase in the AUC of doxorubicin.\n\n###\n\n", " mechanism END"]
["Caution is recommended when administering doxorubicin with NEXAVAR.\n\n###\n\n", " advise END"]
["In a pharmacokinetic study of 18 chronic hepatitis C patients concomitantly receiving methadone, treatment with PEG-Intron once weekly for 4 weeks was associated with a mean increase of 16% in methadone AUC;\n\n###\n\n", " mechanism END"]
["In a formal, single-dose interaction study (n = 6 males) the clearance of mexiletine was decreased by 38% following the coadministration of fluvoxamine, an inhibitor of CYP1A2.\n\n###\n\n", " mechanism END"]
["When phenytoin or other hepatic enzyme inducers such as rifampin and phenobarbital have been taken concurrently with Mexitil   , lowered Mexitil    plasma levels have been reported.\n\n###\n\n", " mechanism END"]
["Concurrent administration of cimetidine and Mexitil    has been reported to increase, decrease, or leave unchanged Mexitil    plasma levels;\n\n###\n\n", " mechanism END"]
["Mexitil    does not alter serum digoxin levels but magnesium-aluminum hydroxide, when used to treat gastrointestinal symptoms due to Mexitil   , has been reported to lower serum digoxin levels.\n\n###\n\n", " mechanism END"]
["Concurrent use of Mexitil    and theophylline may lead to increased plasma theophylline levels.\n\n###\n\n", " mechanism END"]
["This increase was observed at the first test point which was the second day after starting Mexitil   . Theophylline plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If Mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil    dose is changed.\n\n###\n\n", " mechanism\nadvise END"]
["Additionally, in one controlled study in five normal subjects and seven patients, the clearance of caffeine was decreased 50% following the administration of Mexitil   .\n\n###\n\n", " mechanism END"]
["Usage with Alcohol: Due to the potential for increased CNS depressants effects, alcohol should be used with caution in patients who are currently receiving pentazocine.\n\n###\n\n", " advise END"]
["Thiabendazole may compete with other drugs, such as theophylline, for sites of metabolism in the liver, thus elevating the serum levels of such compounds to potentially toxic levels.\n\n###\n\n", " mechanism END"]
["Therefore, when concomitant use of thiabendazole and xanthine derivatives is anticipated, it may be necessary to monitor blood levels and/or reduce the dosage of such compounds.\n\n###\n\n", " advise END"]
["Mild hepatotoxicity has been reported in some patients when lorazepam and pyrimethamine were administered concomitantly.\n\n###\n\n", " effect END"]
["Posicor inhibits some of the liver's ability to metabolize some other drugs - terfenadine, astemizole, cisapride, cyclosporine, and tricyclic antidepressants.\n\n###\n\n", " mechanism END"]
["Trilostane may interact with aminoglutethimide or mitotane (causing too great a decrease in adrenal function).\n\n###\n\n", " int END"]
["Concomitant administration of substances that are also tubularly secreted (e.g., probenecid) could potentially result in delayed clearance of ALIMTA.\n\n###\n\n", " mechanism END"]
["Although ibuprofen (400 mg qid) can be administered with ALIMTA in patients with normal renal function (creatinine clearance    80 mL/min), caution should be used when administering ibuprofen concurrently with ALIMTA to patients with mild to moderate renal insufficiency (creatinine clearance from 45 to 79 mL/min).\n\n###\n\n", " advise END"]
["Patients with mild to moderate renal insufficiency should avoid taking NSAIDs with short elimination half-lives for a period of 2 days before, the day of, and 2 days following administration of ALIMTA.\n\n###\n\n", " advise END"]
["In the absence of data regarding potential interaction between ALIMTA and NSAIDs with longer half-lives, all patients taking these NSAIDs should interrupt dosing for at least 5 days before, the day of, and 2 days following ALIMTA administration.\n\n###\n\n", " advise END"]
["Ritalin may decrease the hypotensive effect of guanethidine.\n\n###\n\n", " effect END"]
["Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine).\n\n###\n\n", " mechanism END"]
["Coumarin-Derivative Anticoagulants: Prolongation of prothrombin time (PT) and International Normalized Ratio (INR) were observed in patients receiving ZOLINZA concomitantly with coumarin-derivative anticoagulants.\n\n###\n\n", " effect END"]
["Physicians should carefully monitor PT and INR in patients concurrently administered ZOLINZA and coumarin derivatives.\n\n###\n\n", " advise END"]
["Other HDAC Inhibitors Severe thrombocytopenia and gastrointestinal bleeding have been reported with concomitant use of ZOLINZA and other HDAC inhibitors (e.g., valproic acid).\n\n###\n\n", " effect END"]
["Increases of 5-FU plasma concentrations by approximately 20% have been observed with doses of 130 mg/m2 ELOXATIN dosed every 3 weeks.\n\n###\n\n", " mechanism END"]
["Cyclosporine: Preliminary data from a XENICAL and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when XENICAL was coadministered with cyclosporine.\n\n###\n\n", " mechanism END"]
["Fat-soluble Vitamin Supplements and Analogues: A pharmacokinetic interaction study showed a 30% reduction in beta-carotene supplement absorption when concomitantly administered with XENICAL.\n\n###\n\n", " mechanism END"]
["XENICAL inhibited absorption of a vitamin E acetate supplement by approximately 60%.\n\n###\n\n", " mechanism END"]
["Therefore, as vitamin K absorption may be decreased with XENICAL, patients on chronic stable doses of warfarin who are prescribed XENICAL should be monitored closely for changes in coagulation parameters.\n\n###\n\n", " mechanism\nadvise END"]
["Terbinafine decreases the clearance of caffeine by 19%.\n\n###\n\n", " mechanism END"]
["Terbinafine increases the clearance of cyclosporine by 15%.\n\n###\n\n", " mechanism END"]
["There have been spontaneous reports of increase or decrease in prothrombin times in patients concomitantly taking oral terbinafine and warfarin, however, a causal relationship between LAMISIL    Tablets and these changes has not been established.\n\n###\n\n", " effect END"]
["Terbinafine clearance is increased 100% by rifampin, a CyP450 enzyme inducer, and decreased 33% by cimetidine, a CyP450 enzyme inhibitor.\n\n###\n\n", " mechanism END"]
["ASPIRIN AND OTHER SALICYLATE DRUGS WILL BE ADDITIVE TO DISALCID AND MAY INCREASE PLASMA CONCENTRATIONS OF SALICYLIC ACID TO TOXIC LEVELS.\n\n###\n\n", " effect END"]
["Salicylates given concomitantly with anticoagulant drugs may predispose to systemic bleeding.\n\n###\n\n", " effect END"]
["Salicylates may enhance the hypoglycemic effect of oral antidiabetic drugs of the sulfonylurea class.\n\n###\n\n", " effect END"]
["Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids.\n\n###\n\n", " mechanism END"]
["Catecholamine-depleting drugs (e.g., reserpine) may have an additive effect when given with beta-blocking agents.\n\n###\n\n", " effect END"]
["Pindolol has been shown to increase serum thioridazine levels when both drugs are co-administered.\n\n###\n\n", " mechanism END"]
["Although specific drug or food interactions with mifepristone have not been studied, on the basis of this drug   s metabolism by CYP 3A4, it is possible that ketoconazole, itraconazole, erythromycin, and grapefruit juice may inhibit its metabolism (increasing serum levels of mifepristone).\n\n###\n\n", " mechanism END"]
["John   s Wort, and certain anticonvulsants (phenytoin, phenobarbital, carbamazepine) may induce mifepristone metabolism (lowering serum levels of mifepristone).\n\n###\n\n", " mechanism END"]
["In addition to bleeding associated with heparin and vitamin K antagonists, drugs that alter platelet function (such as aspirin, dipyridamole, and abciximab) may increase the risk of bleeding if administered prior to or after Retavase    therapy.\n\n###\n\n", " effect END"]
["The occurrence of stupor, muscular rigidity, severe agitation, and elevated temperature has been reported in some patients receiving the combination of selegiline and meperidine.\n\n###\n\n", " effect END"]
["This is typical of the interaction of meperidine and MAOIs.\n\n###\n\n", " int END"]
["Severe toxicity has also been reported in patients receiving the combination of tricyclic antidepressants and ELDEPRYL and selective serotonin reuptake inhibitors and ELDEPRYL.\n\n###\n\n", " effect END"]
["One case of hypertensive crisis has been reported in a patient taking the recommended doses of selegiline and a sympathomimetic medication (ephedrine).\n\n###\n\n", " effect END"]
["Caution should be exercised when administering ZADAXIN therapy in combination with other immunomodulating drugs.\n\n###\n\n", " advise END"]
["Caution should be observed in administering DEMSER to patients receiving phenothiazines or haloperidol because the extrapyramidal effects of these drugs can be expected to be potentiated by inhibition of catecholamine synthesis.\n\n###\n\n", " advise END"]
["Concurrent use of DEMSER with alcohol or other CNS depressants can increase their sedative effects.\n\n###\n\n", " effect END"]
["The metabolism of Metopirone is accelerated by phenytoin;\n\n###\n\n", " mechanism END"]
["Metopirone inhibits the glucuronidation of acetaminophen and could possibly potentiate acetaminophen toxicity.\n\n###\n\n", " mechanism\neffect END"]
["Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist);\n\n###\n\n", " advise END"]
["Co-administration of oral ketoconazole 200 mg twice daily increased retapamulin geometric mean AUC(0-24) and Cmax by 81% after topical application of retapamulin ointment, 1% on the abraded skin of healthy adult males.\n\n###\n\n", " mechanism END"]
["A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.\n\n###\n\n", " mechanism\nadvise END"]
["Dose adjustment of Zemplar Capsules may be required, and iPTH and serum calcium concentrations should be closely monitored if a patient initiates or discontinues therapy with a strong CYP3A4 inhibitor such as ketoconazole.\n\n###\n\n", " advise END"]
["Drugs that impair intestinal absorption of fat-soluble vitamins, such as cholestyramine, may interfere with the absorption of Zemplar Capsules.\n\n###\n\n", " mechanism END"]
["Caution is advised for patients receiving high-dose aspirin and methazolamide concomitantly, as anorexia, tachypnea, lethargy, coma and death have been reported with concomitant use of high-dose aspirin and carbonic anhydrase inhibitors.\n\n###\n\n", " advise\neffect END"]
["However, interactions may be expected and FLOMAX capsules should NOT be used in combination with other alpha-adrenergic blocking agents.\n\n###\n\n", " advise END"]
["Therefore, FLOMAX capsules should be used with caution in combination with cimetidine, particularly at doses higher than 0.4 mg.\n\n###\n\n", " advise END"]
["Therefore, caution should be exercised with concomitant administration of warfarin and FLOMAX capsules.\n\n###\n\n", " advise END"]
["Limited published data indicate that GH treatment increases cytochrome P450 (CP450) mediated antipyrine clearance in man.\n\n###\n\n", " mechanism END"]
["These data suggest that GH administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, cyclosporin).\n\n###\n\n", " mechanism END"]
["The CNS depressant effects of oxycodone hydrochloride may be additive with that of other CNS depressants..\n\n###\n\n", " effect END"]
["Use with Other Central Nervous System Depressants: The depressant effects of morphine are potentiated by the presence of other CNS depressants such as alcohol, sedatives, antihistaminics, or psychotropic drugs.\n\n###\n\n", " effect END"]
["Use of neuroleptics in conjunction with oral morphine may increase the risk of respiratory depression, hypotension and profound sedation or coma.\n\n###\n\n", " effect END"]
["Interaction with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic.\n\n###\n\n", " advise END"]
["Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and sumatriptan within 24 hours of each other should be avoided.\n\n###\n\n", " advise END"]
["MAO-A inhibitors reduce sumatriptan clearance, significantly increasing systemic exposure.\n\n###\n\n", " mechanism END"]
["Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan.\n\n###\n\n", " advise\neffect END"]
["If concomitant treatment with sumatriptan and an SSRI is clinically warranted, appropriate observation of the patient is advised.\n\n###\n\n", " advise END"]
["Antacids: Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium-aluminum containing antacids (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when Myfortic was administered alone under fasting conditions.\n\n###\n\n", " mechanism END"]
["It is recommended that Myfortic and antacids not be administered simultaneously.\n\n###\n\n", " advise END"]
["Azathioprine/Mycophenolate Mofetil: Given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil.\n\n###\n\n", " advise END"]
["Therefore, do not administer Myfortic with cholestyramine or other agents that may interfere with enterohepatic recirculation or drugs that may bind bile acids, for example bile acid sequestrates or oral activated charcoal, because of the potential to reduce the efficacy of Myfortic.\n\n###\n\n", " advise END"]
["However, in a drug-drug interaction study, mean levonorgesterol AUC was decreased by 15% when coadministered with mycophenolate mofetil.\n\n###\n\n", " mechanism END"]
["Therefore, it is recommended that oral contraceptives are co- administered with Myfortic with caution and additional birth control methods be considered.\n\n###\n\n", " advise END"]
["Live Vaccines: During treatment with Myfortic, the use of live attenuated vaccines should be avoided and patients should be advised that vaccinations may be less effective.\n\n###\n\n", " advise END"]
["Although this has not occurred in in vitro studies with coumarin-type anticoagulants, interactions with coumarin-type anticoagulants have been reported with FELDENE since marketing, therefore, physicians should closely monitor patients for a change in dosage requirements when administering FELDENE to patients on coumarin-type anticoagulants and other highly protein-bound drugs.\n\n###\n\n", " int\nadvise END"]
["Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels.\n\n###\n\n", " mechanism END"]
["It is recommended that plasma lithium levels be monitored when initiating, adjusting and discontinuing FELDENE.\n\n###\n\n", " advise END"]
["Vasopressors, particularly metaraminol, may cause serious cardiac arrhythmias during halothane anesthesia and therefore should be used only with great caution or not at all.\n\n###\n\n", " effect END"]
["MAO Inhibitors - The pressor effect of sympathomimetic pressor amines is markedly potentiated in patients receiving monoamine oxidase inhibitors (MAOI).\n\n###\n\n", " effect END"]
["The pressor response of adrenergic agents may also be potentiated by tricyclic antidepressants.\n\n###\n\n", " effect END"]
["Acromegalic patients with diabetes mellitus being treated with insulin and/or oral hypoglycemic agents may require dose reductions of these therapeutic agents after the initiation of therapy with SOMAVERT.\n\n###\n\n", " advise END"]
["In clinical studies, patients on opioids often needed higher serum pegvisomant concentrations to achieve appropriate IGF-I suppression compared with patients not receiving opioids.\n\n###\n\n", " mechanism END"]
["Digoxin: There was a slight increase in the area under the curve (AUC, 11%) and mean peak drug concentration (Cmax, 18%) of digoxin with the co-administration of 100 mg sitagliptin for 10 days.\n\n###\n\n", " mechanism END"]
["Limited evidence suggests that ascorbic acid may influence the intensity and duration of action of bishydroxycoumarin.\n\n###\n\n", " mechanism END"]
["Vindesine can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - Live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the vaccine\n\n###\n\n", " int END"]
["Use of potassium-sparing diuretics (spironolactone, triamterene, amiloride) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia.\n\n###\n\n", " effect END"]
["Lithium: Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium.\n\n###\n\n", " effect END"]
["If a diuretic is also used, the risk of lithium toxicity may be increased.\n\n###\n\n", " effect END"]
["Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).\n\n###\n\n", " int\neffect END"]
["Alcohol: Concomitant administration of alcohol (equivalent to 60 g) had a minimal effect on plasma levels of mirtazapine (15 mg) in 6 healthy male subjects.\n\n###\n\n", " mechanism END"]
["However, the impairment of cognitive and motor skills produced by REMERON    were shown to be additive with those produced by alcohol.\n\n###\n\n", " effect END"]
["Accordingly, patients should be advised to avoid alcohol while taking REMERON SolTab. Diazepam: Concomitant administration of diazepam (15 mg) had a minimal effect on plasma levels of mirtazapine (15 mg) in 12 healthy subjects.\n\n###\n\n", " advise\nmechanism END"]
["However, the impairment of motor skills produced by REMERON has been shown to be additive with those caused by diazepam.\n\n###\n\n", " effect END"]
["Accordingly, patients should be advised to avoid diazepam and other similar drugs while taking REMERON SolTab.\n\n###\n\n", " advise END"]
["Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL).\n\n###\n\n", " advise END"]
["Concurrent administration of bacteriostatic antibiotics (e.g., erythromycin, tetracycline) may diminish the bactericidal effects of penicillins by slowing the rate of bacterial growth.\n\n###\n\n", " effect END"]
["Penicillin blood levels may be prolonged by concurrent administration of probenecid which blocks the renal tubular secretion of penicillins.\n\n###\n\n", " mechanism END"]
["Drug Interactions: Women on oral contraceptives have shown a significant increase in plasma vitamin A levels.\n\n###\n\n", " mechanism END"]
["Concomitant administration of CHEMET with other chelation therapy, such as CaNa 2 EDTA is not recommended.\n\n###\n\n", " advise END"]
["When methyldopa is used with other antihypertensive drugs, potentiation of antihypertensive effect may occur.\n\n###\n\n", " effect END"]
["Patients may require reduced doses of anesthetics when on methyldopa.\n\n###\n\n", " advise END"]
["When methyldopa and lithium are given concomitantly the patient should be carefully monitored for symptoms of lithium toxicity.\n\n###\n\n", " advise END"]
["Several studies demonstrate a decrease in the bioavailability of methyldopa when it is ingested with ferrous sulfate or ferrous gluconate.\n\n###\n\n", " mechanism END"]
["Coadministration of methyldopa with ferrous sulfate or ferrous gluconate is not recommended.\n\n###\n\n", " advise END"]
["norepinephrine and dobutamine are incompatible with sodium bicarbonate solution.\n\n###\n\n", " int END"]
["The bioavailability of SKELID is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before SKELID.\n\n###\n\n", " mechanism END"]
["Aspirin may decrease bioavailability of SKELID by up to 50% when taken 2 hours after SKELID.\n\n###\n\n", " mechanism END"]
["The bioavailability of SKELID is increased 2-4 fold by indomethacin but is not significantly altered by coadministration of diclofenac.\n\n###\n\n", " mechanism END"]
["Tetracycline, a bacteriostatic antibiotic, may antagonize the bactericidal effect of penicillin and concurrent use of these drugs should be avoided.\n\n###\n\n", " effect END"]
["Scopolamine should be used with care in patients taking other drugs that are capable of causing CNS effects such as sedatives, tranquilizers, or alcohol.\n\n###\n\n", " advise END"]
["The induction dose requirements of DIPRIVAN Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with narcotics (eg, morphine, meperidine, and fentanyl, etc.)\n\n###\n\n", " effect END"]
["During maintenance of anesthesia or sedation, the rate of DIPRIVAN Injectable Emulsion administration should be adjusted according to the desired level of anesthesia or sedation and may be reduced in the presence of supplemental analgesic agents (eg, nitrous oxide or opioids).\n\n###\n\n", " advise END"]
["However, increased prothrombin time and bleeding have been reported in patients on concomitant TOLECTIN and warfarin therapy.\n\n###\n\n", " effect END"]
["Therefore, caution should be exercised when administering TOLECTIN to patients on anticoagulants.\n\n###\n\n", " advise END"]
["Caution should be used if TOLECTIN is administered concomitantly with methotrexate.\n\n###\n\n", " advise END"]
["TOLECTIN and other nonsteroidal anti-inflammatory drugs have been reported to reduce the tubular secretion of methotrexate in an animal model, possibly enhancing the toxicity of methotrexate.\n\n###\n\n", " mechanism END"]
["Thiazide diuretics may accentuate the orthostatic hypotension that may occur with phenothiazines.\n\n###\n\n", " effect END"]
["Antihypertensive effects of guanethidine and related compounds may be counteracted when phenothiazines are used concomitantly.\n\n###\n\n", " effect END"]
["Concomitant administration of propranolol with phenothiazines results in increased plasma levels of both drugs.\n\n###\n\n", " mechanism END"]
["In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole.\n\n###\n\n", " effect END"]
["Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue.\n\n###\n\n", " effect END"]
["TOBI should not be administered concomitantly with ethacrynic acid, furosemide, urea, or mannitol.\n\n###\n\n", " advise END"]
["An inhibitor of CYP2C8 (such as gemfibrozil) may increase the AUC of rosiglitazone and an inducer of CYP2C8 (such as rifampin) may decrease the AUC of rosiglitazone.\n\n###\n\n", " mechanism END"]
["Cholestyramine: Cholestyramine causes a 60% reduction in the absorption and enterohepatic cycling of raloxifene and should not be coadministered with EVISTA.\n\n###\n\n", " mechanism\nadvise END"]
["If EVISTA is given concurrently with warfarin, prothrombin time should be monitored.\n\n###\n\n", " advise END"]
["Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, diazepam, and diazoxide.\n\n###\n\n", " advise END"]
["Probenecid competes with meropenem for active tubular secretion and thus inhibits the renal excretion of meropenem.\n\n###\n\n", " mechanism END"]
["Therefore, the coadministration of probenecid with meropenem is not recommended.\n\n###\n\n", " advise END"]
["There is evidence that meropenem may reduce serum levels of valproic acid to subtherapeutic levels (therapeutic range considered to be 50 to 100    g/mL total valproate).\n\n###\n\n", " mechanism END"]
["Other beta adrenergic aerosol bronchodilators should not be used concomitantly with Alupent    (metaproterenol sulfate USP) because they may have additive effects.\n\n###\n\n", " advise END"]
["Beta adrenergic agonists should be administered with caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants, since the action of beta adrenergic agonists on the vascular system may be potentiated.\n\n###\n\n", " advise END"]
["If ZEMURON    is administered following administration of succinylcholine, it should not be given until recovery from succinylcholine has been observed.\n\n###\n\n", " advise END"]
["Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased.\n\n###\n\n", " mechanism END"]
["However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3  Tramadol: Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron.\n\n###\n\n", " effect END"]
["Administration of paclitaxel in combination with HERCEPTIN resulted in a two-fold decrease in HERCEPTIN clearance in a non-human primate study and in a 1.5-fold increase in HERCEPTIN serum levels in clinical studies.\n\n###\n\n", " mechanism END"]
["Concomitant administrations not recommended:  - Terfenadine and astemizole: Certain macrolides interact with terfenadine and astemizole leading to increased serum concentrations of the latter.\n\n###\n\n", " int END"]
["Although such a reaction has not been demonstrated with roxithromycin, concomitant administration of roxithromycin with terfenadine or astemizole is not recommended.\n\n###\n\n", " advise END"]
["- Cisapride, pimozide: Other drugs such as cisapride or pimozide, which are metabolised by hepatic CYP3A isozymes have been associated with QT interval prolongation and/or cardiac arrythmias (typically torsades de pointe) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme, including some macrolide antibacterials.\n\n###\n\n", " mechanism END"]
["Some anticonvulsants may interact with Mephenytoin.\n\n###\n\n", " int END"]
["Mephenytoin may also affect the effects of other drugs, which include some steroid medications, warfarin, certain heart medicines, birth control pills, anti-infective medicines, furosemide and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here.\n\n###\n\n", " effect END"]
["Use of Anticoagulants and Antiplatelet Agents -- Streptase, Streptokinase, alone or in combination with antiplatelet agents and anticoagulants, may cause bleeding complications.\n\n###\n\n", " effect END"]
["The addition of aspirin to Streptokinase causes a minimal increase in the risk of minor bleeding (3.9% vs. 3.1%), but does not appear to increase the incidence of major bleeding (see\n\n###\n\n", " effect END"]
["MAO inhibitors and beta adrenergic blockers increase the effects of pseudoephedrine.\n\n###\n\n", " effect END"]
["Sympathomimetics may reduce the antihypertensive effects of methyldopa, mecamylamine, reserpine and veratrum alkaloids.\n\n###\n\n", " effect END"]
["Because tetracyclines have been shown to depress plasma prothrombin activity, patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage.\n\n###\n\n", " advise END"]
["Since bacteriostatic drugs may interfere with the bactericidal action of penicillin, it is advisable to avoid giving tetracycline class drugs in conjunction with penicillin.\n\n###\n\n", " advise END"]
["Absorption of tetracyclines is impaired by antacids containing aluminum, calcium or magnesium, and iron-containing preparations.\n\n###\n\n", " mechanism END"]
["The concurrent use of tetracycline and methoxyflurane has been reported to result in fatal renal toxicity.\n\n###\n\n", " effect END"]
["Concurrent use of tetracyclines with oral contraceptives may render oral contraceptives less effective.\n\n###\n\n", " effect END"]
["The concomitant use of Sanctura with other anticholinergic agents that produce dry mouth, constipation, and other anticholinergic pharmacological effects may increase the frequency and/or severity of such effects.\n\n###\n\n", " effect END"]
["Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir).\n\n###\n\n", " mechanism END"]
["DRUG INTERACTIONS  There are no known drug/drug interactions with oral ALKERAN  Vaccinations with live organism vaccines are not recommended in immunocompromised individuals  Nalidixic acid together with high-dose intravenous melphalan has caused deaths in children due to haemorrhagic enterocolitis.\n\n###\n\n", " effect END"]
["Impaired renal function has been described in bone marrow transplant patients who were conditioned with high-dose intravenous melphalan and who subsequently received cyclosporin to prevent graft-versus-host disease\n\n###\n\n", " effect END"]
["Drug Interactions: Inhibitors of CYP3A4 Isozymes: Caution is advised when midazolam is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system (ie, some drugs in the drug classes of azole antimycotics, protease inhibitors, calcium channel antagonists, and macrolide antibiotics).\n\n###\n\n", " advise END"]
["Drugs such as erythromycin, diltiazem, verapamil, ketoconazole, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam.\n\n###\n\n", " mechanism END"]
["Although not studied, the potent cytochrome P450 3A4 inhibitors ritonavir and nelfinavir may cause intense and prolonged sedation and respiratory depression due to a decrease in plasma clearance of midazolam.\n\n###\n\n", " mechanism END"]
["Inducers of CYP3A4 Isozymes: Cytochrome P450 inducers, such as rifampin, carbamazepine, and phenytoin, induce metabolism and caused a markedly decreased C max and AUC of oral midazolam in adult studies.\n\n###\n\n", " mechanism END"]
["The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol.\n\n###\n\n", " effect END"]
["Drugs which may potentiate the myeloproliferative effects of Leukine, such as lithium and corticosteroids, should be used with caution.\n\n###\n\n", " effect END"]
["These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;\n\n###\n\n", " effect END"]
["one fatality has been reported from hypoglycemia in association with combined DIFLUCAN and glyburide use.\n\n###\n\n", " effect END"]
["DIFLUCAN reduces the metabolism of tolbutamide, glyburide, and glipizide and increases the plasma concentration of these agents.\n\n###\n\n", " mechanism END"]
["When DIFLUCAN is used concomitantly with these or other sulfonylurea oral hypoglycemic agents, blood glucose concentrations should be carefully monitored and the dose of the sulfonylurea should be adjusted as necessary.\n\n###\n\n", " advise END"]
["Coumarin-type anticoagulants: Prothrombin time may be increased in patients receiving concomitant DIFLUCAN and coumarin-type anticoagulants.\n\n###\n\n", " effect END"]
["In post-marketing experience, as with other azole antifungals, bleeding events (bruising, epistaxis, gastrointestinal bleeding, hematuria, and melena) have been reported in association with increases in prothrombin time in patients receiving fluconazole concurrently with warfarin.\n\n###\n\n", " effect END"]
["Careful monitoring of prothrombin time in patients receiving DIFLUCAN and coumarin-type anticoagulants is recommended.\n\n###\n\n", " advise END"]
["Phenytoin: DIFLUCAN increases the plasma concentrations of phenytoin.\n\n###\n\n", " mechanism END"]
["Careful monitoring of phenytoin concentrations in patients receiving DIFLUCAN and phenytoin is recommended.\n\n###\n\n", " advise END"]
["Cyclosporine: DIFLUCAN may significantly increase cyclosporine levels in renal transplant patients with or without renal impairment.\n\n###\n\n", " mechanism END"]
["Careful monitoring of cyclosporine concentrations and serum creatinine is recommended in patients receiving DIFLUCAN and cyclosporine.\n\n###\n\n", " advise END"]
["Rifampin: Rifampin enhances the metabolism of concurrently administered DIFLUCAN.\n\n###\n\n", " mechanism END"]
["Depending on clinical circumstances, consideration should be given to increasing the dose of DIFLUCAN when it is administered with rifampin.\n\n###\n\n", " advise END"]
["Theophylline: DIFLUCAN increases the serum concentrations of theophylline.\n\n###\n\n", " mechanism END"]
["Careful monitoring of serum theophylline concentrations in patients receiving DIFLUCAN and theophylline is recommended.\n\n###\n\n", " advise END"]
["Terfenadine: Because of the occurrence of serious cardiac dysrhythmias secondary to prolongation of the QTc interval in patients receiving azole antifungals in conjunction with terfenadine, interaction studies have been performed.\n\n###\n\n", " effect END"]
["Another study at a 400-mg and 800-mg daily dose of fluconazole demonstrated that DIFLUCAN taken in doses of 400 mg per day or greater significantly increases plasma levels of terfenadine when taken concomitantly.\n\n###\n\n", " mechanism END"]
["The combined use of fluconazole at doses of 400 mg or greater with terfenadine is contraindicated.\n\n###\n\n", " advise END"]
["The coadministration of fluconazole at doses lower than 400 mg/day with terfenadine should be carefully monitored.\n\n###\n\n", " advise END"]
["Cisapride: There have been reports of cardiac events, including torsade de pointes in patients to whom fluconazole and cisapride were coadministered.\n\n###\n\n", " effect END"]
["A controlled study found that concomitant fluconazole 200 mg once daily and cisapride 20 mg four times a day yielded a significant increase in cisapride plasma levels and prolongation of QTc interval.\n\n###\n\n", " mechanism END"]
["The combined use of fluconazole with cisapride is contraindicated.\n\n###\n\n", " advise END"]
["Astemizole: The use of fluconazole in patients concurrently taking astemizole or other drugs metabolized by the cytochrome P450 system may be associated with elevations in serum levels of these drugs.\n\n###\n\n", " mechanism END"]
["Rifabutin: There have been reports of uveitis in patients to whom fluconazole and rifabutin were coadministered.\n\n###\n\n", " effect END"]
["Patients receiving rifabutin and fluconazole concomitantly should be carefully monitored.\n\n###\n\n", " advise END"]
["Tacrolimus: There have been reports of nephrotoxicity in patients to whom fluconazole and tacrolimus were coadministered.\n\n###\n\n", " effect END"]
["Patients receiving tacrolimus and fluconazole concomitantly should be carefully monitored.\n\n###\n\n", " advise END"]
["Short-acting Benzodiazepines: Following oral administration of midazolam, fluconazole resulted in substantial increases in midazolam concentrations and psychomotor effects.\n\n###\n\n", " mechanism END"]
["This effect on midazolam appears to be more pronounced following oral administration of fluconazole than with fluconazole administered intravenously.\n\n###\n\n", " effect END"]
["If short-acting benzodiazepines, which are metabolized by the cytochrome P450 system, are concomitantly administered with fluconazole, consideration should be given to decreasing the benzodiazepine dosage, and the patients should be appropriately monitored.\n\n###\n\n", " advise END"]
["Fluconazole tablets coadministered with ethinyl estradiol- and levonorgestrel-containing oral contraceptives produced an overall mean increase in ethinyl estradiol and levonorgestrel levels;\n\n###\n\n", " mechanism END"]
["While there is evidence that fluconazole can inhibit the metabolism of ethinyl estradiol and levonorgestrel, there is no evidence that fluconazole is a net inducer of ethinyl estradiol or levonorgestrel metabolism.\n\n###\n\n", " mechanism END"]
["Although a causal relationship has not been established, there have been reports of bleeding and/or prolonged prothrombin time in patients treated with TRENTAL with and without anticoagulants or platelet aggregation inhibitors.\n\n###\n\n", " effect END"]
["Concomitant administration of TRENTAL and theophylline-containing drugs leads to increased theophylline levels and theophylline toxicity in some individuals.\n\n###\n\n", " mechanism END"]
["ACE inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of angiotensin-converting enzyme (ACE) inhibitors.\n\n###\n\n", " effect END"]
["This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE inhibitors.\n\n###\n\n", " advise END"]
["Aspirin: Concomitant administration of aspirin (1000 mg TID) to healthy volunteers tended to increase the AUC (10%) and Cmax (24%) of meloxicam.\n\n###\n\n", " mechanism END"]
["however, as with other NSAIDs, concomitant administration of meloxicam and aspirin is not generally recommended because of the potential for increased adverse effects.\n\n###\n\n", " advise END"]
["Concomitant administration of low-dose aspirin with MOBIC may result in an increased rate of GI ulceration or other complications, compared to use of MOBIC alone.\n\n###\n\n", " effect END"]
["Cholestyramine: Pretreatment for four days with cholestyramine significantly increased the clearance of meloxicam by 50%.\n\n###\n\n", " mechanism END"]
["Furosemide: Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazide diuretics in some patients.\n\n###\n\n", " effect END"]
["Nevertheless, during concomitant therapy with furosemide and MOBIC, patients should be observed closely for signs of declining renal function, as well as to assure diuretic efficacy.\n\n###\n\n", " advise END"]
["Lithium: In clinical trials, NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance.\n\n###\n\n", " mechanism END"]
["In a study conducted in healthy subjects, mean pre-dose lithium concentration and AUC were increased by 21% in subjects receiving lithium doses ranging from 804 to 1072 mg BID with meloxicam 15 mg QD as compared to subjects receiving lithium alone.\n\n###\n\n", " mechanism END"]
["Patients on lithium treatment should be closely monitored when MOBIC is introduced or withdrawn.\n\n###\n\n", " advise END"]
["Warfarin: Anticoagulant activity should be monitored, particularly in the first few days after initiating or changing MOBIC therapy in patients receiving warfarin or similar agents, since these patients are at an increased risk of bleeding.\n\n###\n\n", " advise END"]
["Caution should be used when administering MOBIC with warfarin since patients on warfarin may experience changes in INR and an increased risk of bleeding complications when a new medication is introduced.\n\n###\n\n", " advise END"]
["When administered concomitantly with ProAmatine   , cardiac glycosides may enhance or precipitate bradycardia, A.V.\n\n###\n\n", " effect END"]
["The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction.\n\n###\n\n", " effect END"]
["ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.\n\n###\n\n", " effect\nmechanism END"]
["Preliminary evidence suggests that cimetidine inhibits mebendazole metabolism and may result in an increase in plasma concentrations of mebendazole.\n\n###\n\n", " mechanism END"]
["Interactions for Vitamin B2 (Riboflavin):  Alcohol - impairs the intestinal absorption of riboflavin\n\n###\n\n", " mechanism END"]
["Probenecid - concurrent use decreases gastrointestinal absorption of riboflavin;\n\n###\n\n", " mechanism END"]
["requirements for riboflavin may be increased in patients receiving probenecid.\n\n###\n\n", " effect END"]
["Anticholinergics or other medications with anticholinergic activity when used concurrently with opioid analgesics may result in increased risk of urinary retention and/or severe constipation, which may lead to paralytic ileus.\n\n###\n\n", " effect END"]
["It has been reported that the incidence of bradycardia was increased when oxymorphone was combined with propofol for induction of anesthesia.\n\n###\n\n", " effect END"]
["In addition, CNS toxicity has been reported (confusion, disorientation, respiratory depression, apnea, seizures) following coadministration of cimetidine with opioid analgesics;\n\n###\n\n", " effect END"]
["Since Celontin (methsuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of phenytoin and phenobarbital).\n\n###\n\n", " advise\nmechanism END"]
["When atropine and pralidoxime are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected when atropine is used alone.\n\n###\n\n", " effect END"]
["2 - 4 The following precautions should be kept in mind in the treatment of anticholinesterase poisoning, although they do not bear directly on the use of pralidoxime: since barbiturates are potentiated by the anticholinesterases, they should be used cautiously in the treatment of convulsions;\n\n###\n\n", " effect END"]
["Reduced absorption of folic acid and digoxin have been reported when those agents were administered concomitantly with sulfasalazine.\n\n###\n\n", " mechanism END"]
["Anticoagulants Anabolic steroids may increase sensitivity to oral anticoagulants.\n\n###\n\n", " effect END"]
["Warfarin: A multidose study of oxandrolone, given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with warfarin, resulted in a mean increase in S-warfarin half-life from 26 to 48 hours and AUC from 4.55 to 12.08 ng*hr/mL: similar increases in R-warfarin half-life and AUC were also detected.\n\n###\n\n", " mechanism END"]
["When oxandrolone therapy is initiated in a patient already receiving treatment with warfarin, the INR or prothrombin time (PT) should be monitored closely and the dose of warfarin adjusted as necessary until a stable target INR or PT has been achieved.\n\n###\n\n", " advise END"]
["Furthermore, in patients receiving both drugs, careful monitoring of the INR or PT, and adjustment of the warfarin dosage if indicated are recommended when the oxandrolone dose is changed or discontinued.\n\n###\n\n", " advise END"]
["Oral hypoglycemic agents Oxandrolone may inhibit the metabolism of oral hypoglycemic agents.\n\n###\n\n", " mechanism END"]
["Methysergide may reverse the analgesic activity of narcotic analgesics.\n\n###\n\n", " effect END"]
["Zidovudine competitively inhibits the intracellular phosphorylation of stavudine.\n\n###\n\n", " effect END"]
["Therefore, use of zidovudine in combination with ZERIT should be avoided.\n\n###\n\n", " advise END"]
["In vitro data indicate that the phosphorylation of stavudine is also inhibited at relevant concentrations by doxorubicin and ribavirin.\n\n###\n\n", " effect END"]
["When administered concurrently, testolactone may increase the effects of oral anticoagulants;\n\n###\n\n", " effect END"]
["Cholestyramine: Concomitant cholestyramine administration decreased the mean AUC of total ezetimibe approximately 55%.\n\n###\n\n", " mechanism END"]
["The incremental LDL-C reduction due to adding ezetimibe to cholestyramine may be reduced by this interaction.\n\n###\n\n", " effect END"]
["Co-administration of ZETIA with fibrates is not recommended until use in patients is studied.\n\n###\n\n", " advise END"]
["Fenofibrate: In a pharmacokinetic study, concomitant fenofibrate administration increased total ezetimibe concentrations approximately 1.5-fold.\n\n###\n\n", " mechanism END"]
["Cyclosporine: The total ezetimibe level increased 12-fold in one renal transplant patient receiving multiple medications, including cyclosporine.\n\n###\n\n", " mechanism END"]
["Patients who take both ezetimibe and cyclosporine should be carefully monitored.\n\n###\n\n", " advise END"]
["However, ketoconazole, a potent inhibitor of cytochrome P450 3A4, may increase plasma levels of mometasone furoate during concomitant dosing.\n\n###\n\n", " mechanism END"]
["SKELAXIN may enhance the effects of alcohol, barbiturates and other CNS depressants.\n\n###\n\n", " effect END"]
